Print

Annual General Meeting of Active Biotech AB

2007-04-20

Board members Sven Andréasson, Mats Arnhög, Professor Klas Kärre, Peter Sjöstrand and Peter Ström were re-elected by the AGM. The AGM also decided to appoint Mats Arnhög as Chairman of the Board.
Magnhild Sandberg-Wollheim was elected as a new member of the Board. She is an associate professor of Neurology and Chief Medical Officer at the neurological clinic at Lund University Hospital. Magnhild Sandberg-Wollheim has forty years' experience of treating patients with multiple sclerosis and her research has largely focused on clinical, immunological and genetic problems of this disease.
Furthermore, the AGM decided that the Election Committee shall be composed of representatives for the three largest owners, as per October 31, as well as the Chairman of the Board. The AGM decided further that the Election Committee shall have the task of proposing a Chairman for the AGM, the Chairman of the Board and other Board members, Board remunerations and, when applicable, Auditors and remuneration for the Auditors.
The AGM approved the Board's proposal concerning guidelines for remuneration to the President and other senior executives. The guidelines essentially conform to the principles already applied by the Group.
The AGM also approved the proposed changes to the terms and conditions of the company's warrants, 2004/2009, 2004/2010 and 2004/2011, which entails that the definition "the Bank," in the terms and conditions for the option program, be changed so it reads "The bank or account-operating institute engaged by the Company from time to time."
Sven Andréasson's President & CEO speech at the AGM (in addition to the Annual Report) can be read in its entirety at www.activebiotech.com.
Lund, April 20, 2007
Active Biotech AB (Publ)
Sven Andréasson
President & CEO
Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, the primary indication being renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex® for RA. In addition, the preclinical development of the I-3D project is conducted in cooperation with Chelsea Therapeutics.

Active Biotech AB (org. no. 556223-9227)
P.O. Box 724, SE-220 07 Lund, Sweden
Tel +46 46-19 20 00
Fax +46 46-19 20 50

pdf



Back